Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by Bank of America Corp DE

Bank of America Corp DE grew its holdings in Progyny, Inc. (NASDAQ:PGNY) by 3.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 952,777 shares of the company’s stock after purchasing an additional 33,668 shares during the quarter. Bank of America Corp DE owned 1.12% of Progyny worth $16,435,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PGNY. Vanguard Group Inc. raised its holdings in Progyny by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company’s stock valued at $149,939,000 after acquiring an additional 48,271 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Progyny by 47.5% in the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock valued at $63,414,000 after purchasing an additional 1,183,558 shares in the last quarter. River Road Asset Management LLC acquired a new stake in shares of Progyny in the 4th quarter valued at $25,529,000. Fort Washington Investment Advisors Inc. OH lifted its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock worth $25,319,000 after purchasing an additional 695,740 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Progyny by 95.7% during the fourth quarter. Barclays PLC now owns 1,382,205 shares of the company’s stock worth $23,843,000 after purchasing an additional 676,048 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Trading Up 1.7%

Shares of NASDAQ PGNY opened at $21.87 on Wednesday. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $30.42. The stock has a 50 day simple moving average of $22.15 and a 200-day simple moving average of $19.85. The company has a market cap of $1.87 billion, a PE ratio of 37.71, a P/E/G ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. During the same period in the previous year, the firm earned $0.17 EPS. Progyny’s revenue for the quarter was up 16.5% on a year-over-year basis. Sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PGNY shares. Canaccord Genuity Group decreased their target price on Progyny from $23.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, May 12th. BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a report on Monday, March 31st. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Finally, Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.45.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.